0001104659-21-076264 8-K 1 20210601 5.07 20210603 20210603 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 8-K 34 001-39202 21992044 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 8-K 1 tm2118448d1_8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2021 ANNOVIS BIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-39202 26-2540421 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) File Number) Identification No.) 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 (Address of Principal Executive Offices, and Zip Code) (610) 727-3913 Registrant’s Telephone Number, Including Area Code Not Applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value ANVS NYSE American $0.0001 per share Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x Item 5.07 Submission of Matters to a Vote of Security Holders On June 1, 2021, Annovis Bio, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). Present at the Annual Meeting in person or by proxy were holders of 5,099,298 shares of common stock of the Company, representing 73.4% of the voting power of the shares of common stock of the Company as of the close of business on April 8, 2021, the record date for the Annual Meeting, and constituting a quorum for the transaction of business. All matters voted upon at the Annual Meeting were approved with the required votes. The matters that were voted upon at the Annual Meeting, and the number of votes cast for, withhold or against, as well as the number of abstentions and broker non-votes, as to each such matter are set forth below. 1. Election of five Directors. The following five nominees were elected to serve as directors of the Company, with the following votes tabulated: For Withhold Broker Non-Vote Michael Hoffman 3,542,541 11,634 1,545,123 Maria Maccecchini 3,547,166 7,009 1,545,123 Claudine Bruck 3,523,084 31,091 1,545,123 Reid McCarthy 3,542,544 11,631 1,545,123 Mark White 3,514,706 39,469 1,545,123 2. Amendment of the 2019 Equity Incentive Plan. The amendment of the 2019 Equity Incentive plan was approved, with the following votes tabulated: For Against Abstain Broker Non-Vote 3,038,703 364,131 151,341 1,545,123 3. Ratification of the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the fiscal year ending December 31, 2021. The appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the fiscal year ending December 31, 2021 was ratified, with the following votes tabulated: For Against Abstain Broker Non-Vote 4,900,798 123,451 75,049 — SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: June 3, 2021 By: /s/ Jeffrey McGroarty Name: Jeffrey McGroarty Title: Chief Financial Officer